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Abstract 1 
Frailty is a major health problem in older people and, as the population ages, 2 
identification of its underlying biological mechanisms will be increasingly important. 3 
DNA methylation patterns within genomic DNA change during ageing and alterations 4 
in DNA methylation, particularly at gene promoter regions, can lead to altered gene 5 
expression. However the importance of altered DNA methylation in frailty is largely 6 
unknown. Using cross-sectional data from the Newcastle 85+ Study (all participants 7 
aged 85 years) frailty was operationalized by the Fried model. DNA methylation 8 
levels were assessed by highly quantitative pyrosequencing at the gene promoter 9 
associated CpG islands from a panel of five age-related methylation marker loci and 10 
at LINE-1 repetitive elements (as a surrogate for genome-wide methylation). While 11 
genome-wide methylation (as assessed at LINE-1 elements) showed no association 12 
with frailty status, there was a clear association between CpG island methylation and 13 
frailty. When compared to participants with CpG island methylation levels in the 14 
combined middle 2 (referent) quartiles, those in the lowest quartile had significantly 15 
decreased odds of frailty (odds ratio 0.47 (95% CI 0.26-0.85); n=321, p=0.013). 16 
Overall this study suggests a potential role for age-related changes in CpG island 17 
methylation in the development of frailty. 18 
 19 
Key words: Ageing, Frailty, DNA methylation, CpG island, epigenetics 20 
 21 
 22 
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Introduction 1 
 Frailty is a major health problem in older people, with growing emphasis on 2 
identifying its underlying mechanisms and prospects for intervention. Frailty is 3 
characterised by an increased vulnerability to stress (Bortz 2002; Fried et al. 2001; 4 
Lipsitz 2002; Walston et al. 2006) which results in an increased risk of adverse 5 
health outcomes such as disability, hospitalisation, institutionalisation and death 6 
(Bandeen-Roche et al. 2006; Fried et al. 2001; Kulminski et al. 2007; Mitnitski et al. 7 
2005; Rockwood et al. 2011; Romero-Ortuno et al. 2011). This vulnerability results 8 
from a decline in homeostatic reserve, secondary to dysregulation in multiple inter-9 
related systems (Bortz 2002; Fried et al. 2001; Lipsitz 2002; Walston et al. 2006). 10 
However, knowledge of the mechanisms underlying frailty remains limited, 11 
particularly at the molecular and cellular levels. Whilst there is no universally 12 
accepted method to identify frailty, the Fried approach is one of the most widely 13 
accepted. Frailty is viewed here as a clinical syndrome - a cluster of specific 14 
symptoms and signs - including shrinking/weight loss, poor endurance/exhaustion, 15 
low physical activity, muscle weakness and slow walking speed (Fried et al. 2001). 16 
 DNA methylation is the addition of a methyl group to the carbon-5 position of 17 
cytosine residues. This produces 5-methylcytosine, which is often referred to as the 18 
5th base in DNA and constitutes about 1% of the human genome (Bird 1996). DNA 19 
methylation occurs almost exclusively at CpG dinucleotides and is an important 20 
epigenetic mechanism for controlling gene expression (Costello and Plass 2001). In 21 
particular, hypermethylation of gene promoters which have high densities of CpG 22 
sites, known as CpG islands, leads to chromatin compaction and consequent loss of 23 
gene expression (Bird and Wolffe 1999). This is a critical mechanism for control of 24 
expression of imprinted genes, for X-chromosome inactivation and for regulation of 25 
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many germ cell specific genes (Gopalakrishnan et al. 2008; Weber et al. 2007). 1 
Although the majority of human genes possess a promoter associated CpG island, 2 
these generally remain methylation free, even in tissues where the associated gene 3 
is not expressed (Bird 1996). In contrast, CpG sites outside of promoter associated 4 
CpG islands are usually methylated. These normal patterns of DNA methylation have 5 
been found to break down during ageing (Fraga and Esteller 2007). This primarily 6 
involves a reduction in genome-wide levels of DNA methylation (Bollati et al. 2009), 7 
found in association with localised increases in DNA methylation, centring on 8 
promoter associated CpG island sequences (Fraga and Esteller 2007). This has led 9 
to the hypothesis that age associated changes in DNA methylation may have an 10 
important role in age-related pathologies. However the importance of altered DNA 11 
methylation in frailty is largely unknown. 12 
 In this study we investigated the potential link between frailty and alterations 13 
in DNA methylation. We used data from the Newcastle 85+ Study, a population-14 
based cohort study capturing detailed information on the health of a large, 15 
representative sample who were all aged around 85 at baseline. We examined two 16 
aspects of DNA methylation. Firstly we quantified methylation at specific cytosine 17 
residues within CpG islands associated with gene transcriptional start sites, using a 18 
panel of genes which we have found to exhibit extensive, age-related increases in 19 
methylation in peripheral blood (Gautrey et al. unpublished). Secondly we quantified 20 
methylation at LINE-1 repetitive elements, which is widely used as a surrogate for 21 
genome-wide DNA methylation levels (Weisenberger et al. 2005). 22 
 23 
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Materials and Methods 1 
 2 
Study population 3 
The methodology for the Newcastle 85+ Study has been reported (Collerton 4 
et al. 2007; Collerton et al. 2009; Davies et al. 2010). In brief, members of the 1921 5 
birth cohort living in Newcastle or North Tyneside (North-East England) were 6 
recruited at around age 85 through general practice patient lists. People living in 7 
institutions and those with cognitive impairment were included. At baseline the 8 
Newcastle 85+ cohort was socio-demographically representative of the local 9 
population and of England and Wales (Collerton et al. 2009). The research complied 10 
with the requirements of the Declaration of Helsinki. Ethical approval was obtained 11 
from the Newcastle and North Tyneside 1 Research Ethics Committee (reference 12 
number 06/Q0905/2). Written informed consent was obtained from participants and 13 
where people lacked capacity to consent, for example because of dementia, a formal 14 
written opinion was sought from a relative or carer. 15 
 16 
Data sources 17 
A multidimensional health assessment - comprising questionnaires, 18 
measurements and a fasting blood sample - was carried out in the participant’s usual 19 
residence by a research nurse.  Data on pre-existing diseases and prescribed 20 
medication were obtained from general practice medical records. 21 
 22 
Frailty Status 23 
Fried frailty status – categorised as robust, pre-frail or frail - was derived using 24 
a modified version of the Cardiovascular Health Study methodology (Collerton et al. 25 
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2012; Fried et al. 2001). In line with the stipulated methodology, participants with 1 
stroke, Parkinson’s Disease, a mini-mental state examination score of less than 18, 2 
or taking drugs for dementia, Parkinson’s Disease or depression were excluded on 3 
the basis that they might score as frail as a result of that disease alone. Full details 4 
of criteria used are reported in supplementary methods. 5 
Derivation of frailty status required data from both the health assessment and 6 
general practice records which was available for 845 participants (Collerton et al. 7 
2009). Of these 845 participants, Fried frailty status could be assigned for 552; 8 
applying the Fried exclusion criteria resulted in loss of 252 participants and an 9 
additional 41 could not be assigned due to missing values on individual Fried criteria. 10 
In comparison to those without Fried status, those with Fried status were less likely 11 
to be resident in a care home, less likely to have impaired cognitive function, had a 12 
lower disease count and were less disabled (Collerton et al. 2012). 13 
 14 
DNA modification and PCR 15 
DNA was extracted from peripheral blood leukocytes. 200ng of genomic DNA 16 
was modified with sodium bisulfite using the MethylampTM One-Step DNA 17 
Modification Kit (Epigentek, Brooklyn, NY, USA) as per the manufacturer’s 18 
instructions. All samples were resuspended in 15l of TE and 1l of this was used for 19 
subsequent PCR reactions. The samples were amplified in 25l volumes containing 20 
1X manufacturer’s buffer, 1 unit of FastStart taq polymerase (Roche, Welwyn Garden 21 
City, UK), 1-4mM MgCl2, 10mM dNTPs, and 75ng of each primer. PCR was 22 
performed with one cycle of 95oC for 6 minutes, 40 cycles of 95oC for 30 seconds, 23 
57-63oC for 30 seconds and 72oC for 30 seconds, followed by one cycle of 72oC for 24 
5 minutes. For each set of primers (see Supplementary Table 1) either the forward or 25 
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reverse primers included a 5’ biotin label to facilitate subsequent analysis by 1 
pyrosequencing. 2 
 3 
Quantitative DNA methylation analysis using pyrosequencing 4 
 Following PCR amplification, sequencing was performed using a PSQ 96MA 5 
pyrosequencer (Qiagen, Hilden, Germany), as per manufacturer’s protocol. For all 6 
loci, assays were performed in duplicate and values averaged between the 7 
duplicates. Only samples that were passed by the pyrosequencer were included and 8 
to further ensure a high degree of accuracy, only runs in which single peak heights 9 
were in excess of 200 were included. Samples in which the duplicates differed by 10 
>2% methylation were repeated one additional time and the average taken across 11 
the three replicates. 12 
 Primer design was performed using the manufacturer’s provided PyroMark 13 
software. For initial assessment of all assays, pyrosequencing was carried out on 14 
samples of known methylation status (5, 10, 15, 20, 50, 70 and 100% methylated) 15 
which were produced by diluting peripheral blood derived DNA (from a young adult 16 
volunteer) into in-vitro methylated DNA (Millipore, Watford, UK). 17 
 DNA methylation was assessed at five promoter associated CpG islands 18 
(EPHA10, HAND2, HOXD4, TUSC3 and TWIST2) using quantitative pyrosequencing 19 
analysis. The five genes were selected from a larger panel of 15 genes previously 20 
assessed for age-related methylation in peripheral blood samples from Newcastle 21 
85+ Study participants (Gautrey et al, unpublished). These five loci were selected as 22 
they showed the most extensive and variable methylation in 85 year olds, and 23 
exhibited a steady and near linear age-related increase in methylation levels in 24 
samples taken from multiple age groups (range birth to 85 years old) (Gautrey et al, 25 
8 
 
unpublished), suggesting that these loci would represent good indicator loci for age-1 
related methylation. For each locus between three and six consecutive CpG sites 2 
were measured and the methylation value for each locus was taken as the mean of 3 
the values for all CpG sites measured at that locus. Methylation values at 4 
consecutive CpG sites were strongly correlated, with correlation coefficients between 5 
consecutive CpG sites ranging from 0.93-0.98 (TWIST2), 0.87-0.93 (TUSC3), 0.63-6 
0.87 (HAND2), 0.80-0.86 (HOXD4), and 0.42-0.64 (EPHA10). Methylation levels 7 
across the five loci also correlated (correlation coefficients between 0.20 and 0.60). 8 
Methylation levels across the five loci were combined (see below) to produce an 9 
overall estimate of the level of age-related CpG island methylation for each 10 
participant. 11 
Of the 759 participants from whom DNA samples were collected, 480 were 12 
analysed for CpG island methylation. The samples analysed were chosen primarily 13 
on the basis of previous cancer diagnosis (n=113), incident cancer diagnosis (n=72) 14 
or as a control group without cancer diagnosis (n=212). Also included were current 15 
smokers (n=24) and participants with a diagnosis of type 2 diabetes (n=58) or 16 
dementia (n=36). 35 participants were included in two of these categories and hence 17 
the total number of samples analysed for CpG island methylation was 480. This set 18 
of samples was analysed primarily to allow an investigation of the link between 19 
altered DNA methylation and cancer in the elderly (Gautrey et al, unpublished). This 20 
was then expanded to include some non-cancer endpoints (smoking, type 2 21 
diabetes, dementia) although only cancer diagnosis was found to correlate with DNA 22 
methylation status. 23 
 24 
Derivation of overall CpG island methylation level 25 
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 The overall level of CpG island methylation for each participant was calculated 1 
by averaging the values for each of the five age-related loci examined. To ensure an 2 
equal contribution for each locus, the values for individual loci were first scaled such 3 
that each had an average value across the population equal to the average value of 4 
all five loci. The scaled values for each of the five loci were then averaged to give an 5 
overall value for each participant. 6 
 7 
Other data reported 8 
Pre-existing diagnoses of diabetes mellitus and cancer (excluding non-9 
melanoma skin cancer) were extracted from the general practice records. A count of 10 
chronic diseases was calculated for each participant (Collerton et al. 2009); the full 11 
list of 18 diseases included is shown in the footnote to Table 1. Cognitive status was 12 
assessed using the standardised mini-mental state examination (Molloy and 13 
Standish 1997).  Body mass index was calculated from measured weight and height 14 
(derived from demi-span). Ethnicity, place of residence, years of education, smoking 15 
status (current smoker, ex-smoker, never), and difficulties with activities of daily living 16 
were obtained by self-report. A disability score (maximum 17) was calculated from 17 
the total number of activities of daily living performed with difficulty, or requiring an 18 
aid or appliance or personal help (Collerton et al. 2009). 19 
The levels of lymphocyte subpopulations in peripheral blood samples taken 20 
from Newcastle 85+ participants were determined using flow-cytometry (Becton 21 
Dickinson FACScan Flow Cytometer), as described before (Martin-Ruiz et al. 2011). 22 
 23 
Data Analysis 24 
The analysed sample (i.e. participants with both Fried status and CpG island 25 
methylation data available) was compared to the sample excluded due to missing 26 
methylation data. The Chi-square or Fisher exact tests, as indicated, were used for 27 
10 
 
nominal variables and the Mann-Whitney U test for ordinal and non-parametric 1 
continuous variables. Potential correlation between LINE-1 and CpG island 2 
methylation was assessed using the Pearson correlation coefficient. To explore the 3 
relationship between frailty and methylation, ordinal logistic regression models were 4 
fitted with Fried frailty status as the dependent variable and quartiled methylation 5 
level as the independent variable. The middle two methylation quartiles were 6 
combined and used as the reference category to facilitate identification of potential 7 
relationships at the top and bottom of the distribution. The odds ratios obtained 8 
represent the odds of being in a frailer Fried category i.e. pre-frail rather than robust 9 
or frail rather than pre-frail. The test of parallel lines was used to check that the 10 
proportional odds assumption was satisfied. Two models are reported: Model 1 was 11 
adjusted for sex, % lymphocytes and previous diagnosis of cancer (excluding non-12 
melanoma skin cancer); and Model 2 was adjusted for sex, % lymphocytes, previous 13 
diagnosis of cancer (excluding non-melanoma skin cancer), educational status, 14 
smoking status and number of chronic diseases. Choice of potential confounders 15 
was made on the basis that DNA methylation in this cohort correlates with % 16 
lymphocytes (R2=0.37, p-value<1x10-40; median % lymphocyte count 28.8% of total 17 
white blood cells, interquartile range 22.5-34.4%) and cancer diagnosis (Gautrey et 18 
al, unpublished), as well as evidence that age-related methylation is influenced by 19 
gender (Tapp et al. 2013). Data from six participants were excluded from the final 20 
analysis as the methylation data and % lymphocyte data came from different blood 21 
samples and the participants thus couldn’t be included in either model 1 or model 2. 22 
P-values less than 0.05 were taken as statistically significant. Data analysis was 23 
conducted using SPSS Version 19 (IBM Inc., Chicago, USA).    24 
25 
11 
 
 1 
Results   2 
 3 
Of the 552 participants with frailty status assigned, CpG island methylation 4 
data was available for 321; these 321 participants formed the sample for the principal 5 
analyses. The characteristics of the 321 participants are shown in Table 1, together 6 
with a comparison to the sample with frailty status assigned but who were not 7 
analysed for CpG island methylation (n=231). Frailty was found in 21.8% (70/321) of 8 
participants, with 58.6% (188/321) defined as pre-frail and the remainder as robust. 9 
Frailty status in 85 year olds is associated with gene promoter associated 10 
CpG island methylation. 11 
There was substantial inter-individual variation in CpG island methylation 12 
levels, with values ranging from 4.8% to 29.1%, and a mean level of 10.7% 13 
(standard deviation 3.0%) (Fig. 1A). Compared to participants in the combined 14 
middle (referent) quartiles, those in the lowest quartile of gene promoter associated 15 
CpG island methylation level had lower odds of frailty. This was observed using the 16 
model adjusted for factors known to influence DNA methylation (i.e. sex, % 17 
lymphocytes and cancer diagnosis) (Model 1: odds ratio (95% confidence interval) 18 
0.47 (0.26-0.85), p-value=0.013) and in the model additionally adjusted for 19 
educational status, smoking status and number of chronic diseases (Model 2: odds 20 
ratio (95% confidence interval) 0.46 (0.25-0.86), p-value=0.016) (Table 2). 21 
As frailty status is derived using five separate criteria, it is possible that the 22 
association found above may be largely driven by an association with a single 23 
criterion, as opposed to the frailty syndrome as a whole. We therefore further 24 
investigated whether CpG island methylation was associated with the individual 25 
criteria used to define the frailty syndrome (shrinking/weight loss, poor 26 
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endurance/exhaustion, low physical activity, weakness, and slow walking speed). 1 
The relationship found between CpG island methylation and the frailty syndrome 2 
appeared to be mirrored in four out of the five frailty criteria (shrinking excepted), 3 
although associations only reached statistical significance for weakness and low 4 
physical activity (slow walking speed was close to significance) (Supplementary 5 
Table 3).  6 
 7 
Frailty status in 85 year olds is not associated with LINE-1 methylation levels 8 
 The relationship between frailty and DNA methylation at gene promoter 9 
associated CpG islands could suggest a role for DNA methylation induced changes 10 
in gene expression in the development of frailty. Alternatively, it may represent a 11 
more general association between frailty and genome-wide levels of DNA 12 
methylation. To explore this possibility the analysis was extended to include 13 
methylation levels at LINE-1 elements. These are the most common repeat elements 14 
present in the human genome and have previously been shown to represent a good 15 
surrogate for genome-wide methylation levels (Weisenberger et al. 2005). 16 
Sufficient DNA was available to assess LINE-1 methylation in the majority 17 
(84.1%, 270/321) of samples with both Fried frailty status and CpG island 18 
methylation data. Comparison of the participants with/without LINE-1 methylation 19 
data showed them to be similar, other than a lower level of disability in the group with 20 
LINE-1 data (Supplementary Table 2).  LINE-1 methylation levels varied from 74.7% 21 
to 85.2%, with a mean level of 80.9% (standard deviation 1.8%) (Fig. 1B). The LINE-22 
1 methylation levels in the Newcastle 85+ study cohort were similar to those reported 23 
for previously analysed cohorts, including elderly individuals (Zhu et al. 2012). No 24 
13 
 
significant correlation was found between the level of CpG island methylation and 1 
LINE-1 methylation (R=-0.096, p=0.12, Fig. 1C). 2 
In contrast with the results for gene promoter associated CpG island 3 
methylation, there was no evidence for an association between LINE-1 methylation 4 
and frailty status (Table 2). This implies that frailty is specifically associated with 5 
methylation changes focussed on gene promoter regions, where it is likely to 6 
influence gene expression patterns, and not with DNA methylation levels as a whole. 7 
 8 
 9 
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Discussion 1 
 Frailty is becoming a major health and societal issue, as the world’s 2 
population ages. However, frailty does not appear to be an inevitable consequence 3 
of ageing. Whilst a quarter to a third of people aged 85 and older are frail, even at 4 
this age the majority of the population are not frail (Collerton et al. 2012; Fried et al. 5 
2001; Song et al. 2010). The underlying causes of frailty, and the reasons for inter-6 
individual differences in the experience of frailty within people of the same age, are 7 
poorly understood. 8 
 Epigenetic mechanisms are an attractive candidate as one of the underlying 9 
causes of frailty. Unlike genetic factors, epigenetic mechanisms are sensitive to 10 
environmental factors, including nutrition and lifestyle, and the epigenome in elderly 11 
individuals will have been re-modelled in response to their lifetime exposures to 12 
different environmental factors (Mathers et al. 2010). In addition, epigenetic factors, 13 
and in particular DNA methylation, vary significantly both cross-sectionally within 14 
populations of the same age and across the life-course (Rakyan et al. 2010). 15 
In this study we have examined the potential associations between frailty and 16 
both promoter specific CpG island methylation and genome-wide methylation (using 17 
LINE-1 elements as a surrogate). We found that lower levels of promoter specific 18 
CpG island methylation were associated with reduced frailty. Promoter methylation is 19 
associated with gene silencing (Bird and Wolffe 1999) and hence the differences in 20 
promoter methylation between frailty categories observed here may reflect 21 
differences in expression of the corresponding genes.  If such differences in 22 
methylation patterns occur in other genes and in multiple tissue types, the 23 
consequential differences in gene expression could play a role in the breakdown of 24 
15 
 
many physiological processes, which is thought to be a key mechanism underlying 1 
frailty (Bortz 2002; Fried et al. 2001; Lipsitz 2002; Walston et al. 2006). 2 
 A second possibility is that alterations in methylation act as a biological 3 
marker for frailty but without playing a direct causative role, for example if there was 4 
a common driving force behind the altered methylation and the development of 5 
frailty. In either case it would be important to determine the extent to which altered 6 
DNA methylation can function as a predictive marker, allowing the detection of 7 
individuals at risk of developing frailty. This will be assessed within the longitudinal 8 
data from the Newcastle 85+ study, by examining the extent to which DNA 9 
methylation levels at baseline predict frailty status at subsequent phases of the 10 
study. Furthermore, long-term studies, initiated in younger populations, will be 11 
required to robustly assess the potential utility of altered DNA methylation as a 12 
predictive marker for frailty as intervention strategies to reduce or prevent frailty may 13 
be more effective if implemented earlier in the life-course. 14 
The Fried frailty syndrome is based on five criteria and it is possible that the 15 
association between CpG island methylation levels and frailty could be primarily 16 
driven by an association with one or a subset of these criteria. Analysis using the 17 
individual criteria found that the relationship between CpG island methylation and the 18 
frailty syndrome appeared to be mirrored in four out of the five individual criteria 19 
(shrinking excepted), although associations only reached statistical significance for 20 
weakness and low physical activity (slow walking speed was close to significance). It 21 
is not possible to formally assess whether the association with CpG island 22 
methylation is stronger for any of the specific criteria than for the syndrome of frailty, 23 
particularly as the low number of participants in the frail category for the individual 24 
criteria reduces the power of this analysis. Whilst there is heterogeneity in the initial 25 
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manifestation of frailty, weakness is the most common first manifestation, with 1 
weakness, low physical activity and slowness tending to precede shrinking and 2 
exhaustion (Xue et al. 2008). This underlines the central role of sarcopaenia in the 3 
frailty phenotype (Xue 2011). Different patterns of accumulation of individual frailty 4 
criteria may represent different causative pathways for frailty, with certain criteria 5 
being more sensitive than others to particular physiological, molecular or cellular 6 
dysregulations resulting from disease and/or ageing (Xue 2011). 7 
 We also found that the association between frailty and methylation was 8 
specific for promoter associated regions, as methylation levels at LINE-1 assays 9 
(used as a surrogate for genome-wide methylation) were not associated with frailty 10 
status. This observation is in apparent conflict with the recent findings of Bellizzi et al 11 
(Bellizzi et al. 2012) who reported an inverse association between genome-wide 12 
DNA methylation and frailty. The apparent difference in findings between the two 13 
studies may reflect the different methodologies used to assess genome-wide DNA 14 
methylation levels. As their surrogate for global DNA methylation, Bellizzi et al 15 
(Bellizzi et al. 2012) used the so-called CpGlobal assay which is based on differential 16 
cutting of DNA by two restriction endonucleases viz. HpaII (which is sensitive to 17 
cytosine methylation) and MspI (which cuts regardless of methylation status). 18 
Previous studies have demonstrated the utility of LINE-1 methylation as a marker of 19 
genome-wide methylation (Weisenberger et al. 2005) and the results obtained in this 20 
study are very similar to results previously reported for LINE-1 methylation in similar 21 
age groups (Zhu et al. 2012). In contrast, the extensive variation in genome-wide 22 
methylation levels reported in the Bellizzi et al study is not consistent with previously 23 
published data, either using the LINE-1 approach or directly measuring total 5-24 
methylcytosine levels by HPLC (Fuke et al. 2004; Weisenberger et al. 2005). 25 
17 
 
Furthermore, the large within-individual changes, over seven years of the lifespan, 1 
which were reported by Bellizzi et al (Bellizzi et al. 2012) are not consistent with the 2 
far more subtle temporal changes in global DNA methylation previously reported by 3 
Bjornsson et al, who interrogated within-individual changes in global DNA 4 
methylation over 11-16 years of adulthood. These authors used the LUMA assay, 5 
which, like the CpGlobal assay used by Bellizzi et al., is also based on differential 6 
cutting of DNA by the restriction endonucleases HpaII  and MspI (Bjornsson et al. 7 
2008). In addition, the HpaII sites targeted by these assays are highly enriched within 8 
CpG islands (Bjornsson et al. 2008) and thus may be more reflective of CpG island 9 
methylation levels than genome-wide methylation status. 10 
 This study suggests that the level of accumulation of CpG island methylation 11 
may influence the development of frailty. However, the factors which drive the 12 
population variability in CpG island methylation, and the relative importance of 13 
genetic and environmental factors, remains unknown. Multiple studies have 14 
examined the possibility that DNA methylation levels may be influenced by 15 
polymorphisms in enzymes regulating one carbon metabolism, which is crucial for 16 
the production of the methyl donors required for the DNA methylation reaction 17 
(Struck et al. 2012), or in the DNA methyltransferase genes themselves. Most of 18 
these studies have focussed on cancer associated DNA methylation changes, and 19 
no clear impact of SNPs on DNA methylation levels has so far been identified 20 
(Huidobro et al. 2013). Recent studies have also examined such SNPs in healthy 21 
individuals. This has identified some potential associations with key metabolites in 22 
the DNA methylation pathway, but what, if any, effect this has on DNA methylation 23 
patterns is still unclear (DeVos et al. 2008; Ho et al. 2011). In addition, several 24 
studies, using genome wide approaches, have reported associations between SNPs 25 
18 
 
and methylation at CpG sites proximally located to the SNP (Boks et al. 2009; Zhang 1 
et al. 2010). However, such SNPs have not been found to correlate with methylation 2 
at multiple loci throughout the genome (Boks et al. 2009) and so could not underlie 3 
the correlations we found in methylation levels between different loci and would likely 4 
have little impact on the average methylation value used in this study. 5 
 A number of other factors could influence DNA methylation levels in the 6 
elderly, such as changes in the relative proportions of the different cell types found in 7 
peripheral blood. Indeed it has been well documented that lymphocyte levels fall in 8 
elderly individuals (Huppert et al. 1998) and furthermore a number of diseases 9 
common in the elderly population, such as cardiovascular disease (Nunez et al. 10 
2011), as well as level of activity (DiPenta et al. 2004) can potentially result in 11 
alterations in the relative proportions of the different cell types. In this study we found 12 
that the percentage of lymphocytes (as a fraction of total white blood cells) was 13 
significantly associated with DNA methylation levels. This correlation was specifically 14 
for total lymphocytes, as the relative proportions of T or B lymphocytes within this 15 
population was not associated with DNA methylation levels (Gautrey et al, 16 
unpublished). To address this, the analysis presented in this paper was adjusted for 17 
the percentage of lymphocytes and thus inter-individual variation in relative cell 18 
counts should not have impacted on the results presented here. 19 
 Strengths of this study include its population-based sample, which included 20 
the institutionalised, and the domiciliary nature of the assessment which avoids the 21 
selection bias inherent in clinic-based assessment of this age group. As all 22 
participants were the same age, all variation detected will represent inter-individual 23 
variation and will not be due to differences in chronological age. Furthermore, by 24 
studying a population of the very old, we are likely to have maximised the extent of 25 
19 
 
age-associated methylation changes. In addition, our analyses were adjusted for a 1 
range of potential confounders, including disease burden. 2 
Some limitations deserve comment. The analysed sample differs from the 3 
sample excluded due to missing data. Higher levels of care home residence, 4 
cognitive impairment and disability in the excluded sample relate to the previously 5 
reported problems operationalizing the Fried model in this age group (Collerton et al. 6 
2012), with lower levels of smoking and disease burden resulting from the 7 
methylation sampling strategy. However, our findings were robust to adjustment for 8 
the key confounders. As in many other investigations (Avila-Funes et al. 2008; 9 
Cawthon et al. 2007; Cigolle et al. 2009; Ensrud et al. 2007; Santos-Eggimann et al. 10 
2009; Wilhelm-Leen et al. 2010), our Fried operationalization was a modification of 11 
the Cardiovascular Health Study methodology as the exact variables were not 12 
collected. However our frailty prevalence was identical to that reported in the 13 
Cardiovascular Health Study for this age group (Fried et al. 2001). 14 
Overall, our results suggest that promoter specific CpG island methylation 15 
levels, but not genome-wide DNA methylation levels, are associated with frailty in the 16 
very old and should be further investigated as a potential underlying cause and/or 17 
predictive marker for the development of frailty. 18 
19 
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Figure legend 
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Fig. 1. Methylation levels in Newcastle 85+ Study participants. A) Distribution of 
CpG island methylation levels (averaged across 5 genes) in the Newcastle 85+ 
Study participants (n=321). B) Distribution of LINE-1 methylation levels in the 
Newcastle 85+ Study participants (n=270). C) Correlation between LINE-1 
methylation and CpG island methylation (n=270). 
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Click here to download high resolution image
Table 1. Comparison of sample populations with or without CPG island methylation data
Sample with Fried 
status and CpG 
island methylation 
data (%) (n=321)
Sample with Fried 
status but without 
CPG island 
methylation data      
(%) (n=231) p value
57.3 (184) 64.1 (148) 0.110a
99.4 (319) 100.0 (231) 0.512b
Place of residence
Standard housing 86.3 (277) 82.7 (191) 0.179a
Sheltered housing 12.5 (40) 13.9 (32)
Resident in care home 1.2 (4) 3.5 (8)
0.237c
12+ 12.9 (41) 12.1 (28)
10-11 24.1 (77) 19.5 (45)
0-9 63.0 (201) 68.4 (158)
Never smoker 30.5 (98) 40.3 (93) 0.002a
Ex-smoker 61.1 (196) 57.6 (133)
Current 8.4 (27) 2.2 (5)
Body mass index (kg/m2) 0.012c
<18.50 5.4 (17) 9.8 (21)
18.50-24.99 48.4 (152) 53.3 (114)
25.00-29.99 33.4 (105) 28.0 (60)
≥30.00 12.7 (40) 8.9 (19)
0.337c
Normal (26-30) 81.1 (258) 84.1 (191)
Mildly impaired (22-25) 15.1 (48) 13.7 (31)
Moderately impaired (18-21) 3.8 (12) 2.2 (5)
Severely impaired (0-17) 0.0 (0) 0.0 (0)
Diabetes Mellitus 21.5 (69) 4.3 (10) <0.001a
Cancer (any previous diagnosis; excluding non-melanoma skin cancer) 25.2 (81) 3.0 (7) <0.001a
5 (3-6) 4 (3-5) 0.001b
2 (0-5) 2 (0-6) 0.713c
Fried frailty status, % (n) 0.591c
Robust 19.6 (63) 16.0 (37)
Pre-frail 58.6 (188) 62.8 (145)
Frail 21.8 (70) 21.2 (49)
e
Number of activities of daily living performed with difficulty or requiring an aid, appliance or personal help, maximum score 17. 
d
18 diseases: hypertension, ischaemic heart disease, cerebrovascular disease, peripheral vascular disease, heart failure, atrial flutter or fibrillation, 
arthritis, osteoporosis, chronic obstructive pulmonary disease or asthma, other respiratory disease, diabetes mellitus, hypothyroidism or 
hyperthyroidism, cancer diagnosed within past 5 years (excluding non-melanoma skin cancer), eye disease, dementia, Parkinson's Disease, renal 
impairment and anaemia. 
Chronic disease count, median (IQR)d 
Disability score, median (IQR)e
Notes : Data are % (n) except where specified; denominators vary due to missing values
a
Chi-square test for no significant difference between samples with and without methylation data 
c
Mann-Whitney U test for no significant difference between samples with and without methylation data 
Cognitive function (mini-mental state examination score)
b
Fisher exact test for no significant difference between samples with and without methylation data 
Female 
White ethnicity
Years of education
Smoking status
Table 1
Click here to download Table: Table 1_Collerton et al.xls 
Table 2. Association between frailty and CpG island methylation levels
CpG island methylation ≤ 8.50 0.47 (0.26 to 0.85) 0.013 0.46 (0.25 to 0.86) 0.016
8.51-11.95 Reference Reference
≥ 11.96 1.63 (0.88 to 3.04) 0.124 1.54 (0.76 to 3.10) 0.232
LINE-1 methylation ≤ 79.88 0.87 (0.51 to 1.57) 0.629 0.71 (0.38 to 1.34) 0.291
79.89-82.22 Reference Reference
≥ 82.23 0.89 (0.51 to 1.57) 0.693 0.79 (0.44 to 1.41) 0.420
Model 1 is adjusted for sex, % lymphocytes and any cancer except non-melanoma skin cancer.
Model 2 is adjusted for sex, % lymphocytes, any cancer except non-melanoma skin cancer, education, 
smoking and total disease count.
Ordinal logistic regression models were fitted with Fried status as the dependent variable and quartiled methylation as the 
independent variable. The middle two methylation quartiles were combined and used as the reference category. 
Model 2 odds ratio 
(95% confidence 
interval)
Model 2 
p value
Model 1 
p value
Model 1 odds ratio (95% 
confidence interval)
Table 2
Click here to download Table: Table 2_Collerton et al.xls 
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